Loading data for PPCB — first visit, this takes a few seconds.
Propanc Biopharma Inc. (PPCB)
NasdaqCM: PPCB
· Real-Time Price · USD
1.16
+0.01 (0.87%)
At close: Aug 18, 2026, 8:00 PM
1.22
+5.17%
Pre-market: 7:43 AM
Propanc Biopharma Inc. (PPCB) Stock Price, Analysis & Data
0.87% (1D)
No data available
| Bid | 0.83 |
| Market Cap | 2.64M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -19.29M |
| Beta | 3.27 |
| EPS (ttm) | 570.5 |
| PE Ratio (ttm) | 0 |
| Forward PE | n/a |
| P/B (ttm) | 0.10 |
| P/S (ttm) | n/a |
| Earnings Date | n/a |
| Ask | 1.45 |
| Volume | 29,621 |
| Avg. Volume (20D) | 3,869,433 |
| Open | 1.12 |
| Previous Close | 1.15 |
| Day's Range | 1.10 - 1.19 |
| 52-Week Range | 0.95 - 142.25 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About PPCB
Propanc Biopharma, Inc., a development-stage biopharmaceutical healthcare company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia. Its lead product candidate is PRP, an intravenous injection proenzyme treatment designed as a therapeutic option in cancer treatment and prevention which has completed pre-clinical studies. The company has a research and collaboration agreemen...
Industry Biotechnology
Sector Healthcare
IPO Date Jan 7, 2013
Employees 1
Stock Exchange NasdaqCM
Ticker Symbol PPCB
Website https://www.propanc.com
Financial Performance
In 2025, Propanc Biopharma's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -58.92M, an increase of 3,136.6%.
Financial Statements